Skye Bioscience, Inc. (SKYE) Stock Forecast
SKYE analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 4.00 / 5 from 4 analysts
- Price target
- $68.00 average of analyst targets
- Upside to target
- +4,287.1% from the latest close
- Next earnings
- November 9, 2026 EPS estimate $-1.12
- 52-week range
- $0.28 – $2.23
SKYE analyst ratings
4 analystsNumber of analysts at each rating.
SKYE price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
SKYE earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$1.12 | −$1.12 | −$1.12 | −$2.59 | +56.8% | 1 |
| Current fiscal year (2026) | −$5.04 | −$5.04 | −$5.04 | −$11.35 | +55.6% | 1 |
| Next fiscal year (2027) | −$7.40 | −$10.80 | −$4.56 | −$5.04 | −46.8% | 4 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
SKYE revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 5 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 5 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 5 |
SKYE EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
SKYE EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$2.01 | −$2.01 | −$2.01 | −$1.12 | −$1.12 | −44.4% | 0 up · 0 down |
| Current fiscal year (2026) | −$8.37 | −$8.37 | −$8.37 | −$5.04 | −$5.04 | −39.8% | 0 up · 0 down |
| Next fiscal year (2027) | −$9.05 | −$9.05 | −$9.05 | −$7.95 | −$7.40 | −18.3% | 2 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
SKYE earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; SKYE beat in 5 of 12.
What analysts expect from SKYE
4 analysts cover Skye Bioscience; their consensus rating is buy (4.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $68.00, 4,287.1% above the latest close of $1.55. Analysts expect earnings of −$5.04 per share for 2026, +55.6% from a year earlier. For 2027 the average estimate is −$7.40 per share. Skye Bioscience beat the EPS estimate in 5 of the last 12 quarters.
Related: SKYE income statement, SKYE key metrics, SKYE chart. See the SKYE stock overview for the latest quote and news.
SKYE forecast FAQ
What is Skye Bioscience's price target?
The average analyst price target for Skye Bioscience is $68.00, 4,287.1% above the latest close of $1.55.
Is Skye Bioscience a buy, hold or sell?
Of 4 analysts covering Skye Bioscience, 2 rate it a strong buy, 0 a buy, 2 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Skye Bioscience's EPS forecast?
Analysts forecast −$5.04 per share for 2026 (range −$5.04 to −$5.04); for 2027 the estimate is −$7.40.
When does Skye Bioscience report earnings?
Skye Bioscience is expected to report results for the quarter ending September 30, 2026 on November 9, 2026 after the market closes; the EPS estimate is $-1.12.
Does Skye Bioscience usually beat earnings estimates?
Skye Bioscience reported EPS at or above the analyst estimate in 5 of the last 12 quarters.